ALZN
Price:
$1.14
Market Cap:
$5.10M
Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001 that is in Phase II clinical trial, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and AL002 that completed preclinical stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system ...[Read more]
Industry
Biotechnology
IPO Date
2021-06-15
Stock Exchange
NASDAQ
Ticker
ALZN
According to Alzamend Neuro, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 3.91M. This represents a change of -34.71% compared to the average of 5.99M of the last 4 quarters.
The mean historical Enterprise Value of Alzamend Neuro, Inc. over the last ten years is 526.30M. The current 3.91M Enterprise Value has changed -25.75% with respect to the historical average. Over the past ten years (40 quarters), ALZN's Enterprise Value was at its highest in in the April 2021 quarter at 994.71M. The Enterprise Value was at its lowest in in the January 2001 quarter at 0.
Average
526.30M
Median
389.39M
Minimum
4.73M
Maximum
1.15B
Discovering the peaks and valleys of Alzamend Neuro, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 195.61%
Maximum Annual Enterprise Value = 1.15B
Minimum Annual Increase = -92.17%
Minimum Annual Enterprise Value = 4.73M
Year | Enterprise Value | Change |
---|---|---|
2024 | 4.73M | -89.86% |
2023 | 46.66M | -39.14% |
2022 | 76.67M | -92.17% |
2021 | 978.51M | 1.74% |
2020 | 961.78M | 21.17% |
2019 | 793.76M | -31.04% |
2018 | 1.15B | 195.61% |
2017 | 389.39M | 16.54% |
The current Enterprise Value of Alzamend Neuro, Inc. (ALZN) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
42.68M
5-year avg
413.67M
10-year avg
526.30M
Alzamend Neuro, Inc.’s Enterprise Value is greater than TRACON Pharmaceuticals, Inc. (-6160275.00), less than Solid Biosciences Inc. (162.10M), less than Kezar Life Sciences, Inc. (31.67M), less than Senti Biosciences, Inc. (49.47M), less than X4 Pharmaceuticals, Inc. (0), less than Inozyme Pharma, Inc. (48.86M), less than Terns Pharmaceuticals, Inc. (187.31M), less than Day One Biopharmaceuticals, Inc. (287.52M), less than HOOKIPA Pharma Inc. (966.48M), greater than Acumen Pharmaceuticals, Inc. (-32690900.00), less than VectivBio Holding AG (126.58M), less than Molecular Partners AG (848.58M), less than Adverum Biotechnologies, Inc. (117.62M), less than Alector, Inc. (103.35M), less than Adagene Inc. (209.01M), less than null (16.31M),
Company | Enterprise Value | Market cap |
---|---|---|
-6160275.00 | $109.72K | |
162.10M | $201.77M | |
31.67M | $49.61M | |
49.47M | $25.24M | |
0 | $68.06M | |
48.86M | $165.10M | |
187.31M | $556.35M | |
287.52M | $1.39B | |
966.48M | $24.23M | |
-32690900.00 | $129.77M | |
126.58M | $1.06B | |
848.58M | $210.86M | |
117.62M | $122.94M | |
103.35M | $211.53M | |
209.01M | $91.20M | |
16.31M | $0 |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Alzamend Neuro, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Alzamend Neuro, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is Alzamend Neuro, Inc.'s Enterprise Value?
What is the highest Enterprise Value for Alzamend Neuro, Inc. (ALZN)?
What is the 3-year average Enterprise Value for Alzamend Neuro, Inc. (ALZN)?
What is the 5-year average Enterprise Value for Alzamend Neuro, Inc. (ALZN)?
How does the current Enterprise Value for Alzamend Neuro, Inc. (ALZN) compare to its historical average?